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ABSTRACT 
AP-1 plays crucial roles in a wide range of cellular processes in breast cancer. Through the dimeric 
basic leucine zipper (bZIP) domain, the mammalian AP-1 proteins bind to DNA and form 
homodimers or heterodimers from the Jun (c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra1, Fra2), ATF 
and MAF family members. AP-1 is involved in several signal transduction pathways to control 
physiological and pathological processes, such as oncogenesis, metastasis and apoptosis. However, the 
mechanistic aspects of the modulatory effect of AP-1 in breast cancer are still not fully understood. 
Thus, to explore genome-wide transcriptional regulatory networks of the transcription factor AP-1 in 
breast cancer may help to identify novel strategies to develop new therapies. 
In Paper I, we established that AP-1 participates in estrogen-dependent gene expression and 
proliferation programs in breast cancer cells. In addition, we identified PKIB (cAMP-dependent 
protein kinase inhibitor-β) as a novel ERα/AP-1 target molecule, which is required for breast cancer 
cell growth.  
In Paper II, we observed, by analyzing publically available datasets, that AP-1 is expressed at high 
levels in basal-like breast cancers and associated with poor clinical outcome. High level expression of 
AP-1 was also found in triple-negative breast cancer (TNBC) cell lines as determined by Western blot 
analysis and qPCR. Using cistrome and transcriptome analyses to investigate the signaling networks of 
AP-1 in TNBC cells, we identified that about 15% of AP-1 binding sites are located in the proximal 5’ 
region of the nearest gene. Gene expression profiling analysis identified differential expression of 419 
and 690 genes upon knockdown of Fra-1 and c-Jun, respectively. Among these genes, 222 genes 
which were regulated by both Fra-1 and c-Jun were associated with cytokine-mediated signaling, type 
I interferon-mediated signaling, chemotaxis, cell adhesion, immune response, cell junction assembly, 
adherens junction organization and inflammatory response. Moreover, we found that proliferative 
phenotypes of TNBC cells were inhibited upon depletion of AP-1. In addition, silencing of AP-1 
reduced the invasion ability both in vitro and in vivo. We further showed that AP-1 activation, 
downstream of the PI3K/Akt and MAPK/ERK pathways, repressed expression of E-cadherin by 
transcriptional upregulation of ZEB2.  
In Paper III, we demonstrated that TNFα activated both the PI3K/Akt and MAPK/ERK signaling 
pathways to induce epithelial-mesenchymal transition (EMT) in TNBC cells via activation of AP-1 
signaling and increased expression of the EMT regulator ZEB2. Based on published data on spliced 
transcripts, two alternatively spliced 5’UTR isoforms of the ZEB2 gene were found to be expressed in 
breast cancer cell lines and breast tumor samples. Using the chromosome conformation capture assay, 
we demonstrated that AP-1, when activated by TNFα bound to a site in promoter 1b of the ZEB2 gene 
where it regulates the expression of both promoter 1b and 1a, the latter via mediating long range 
chromatin interactions.   
In Paper IV, We defined that c-Jun regulated nearly a third of the TNFα-elicited transcriptome. 
Expression of a c-Jun-regulated pro-invasion gene set was shown to be strongly associated with 
clinical outcomes in TNBCs. We demonstrated that c-Jun drives TNFα-mediated TNBC malignant 
characteristics by transcriptional regulation of Ninj1. As exemplified by the c-Jun bound CXC 
chemokine genes clustered on chromosome 4, we demonstrated that NF-κB might be a pioneer factor 
and was required for the regulation of TNFα-inducible inflammatory genes, whereas c-Jun had little 
effect on TNFα-inducible inflammatory genes.  
In conclusion, our studies give additional insights into the molecular mechanisms of AP-1 in relation 
to breast cancer cellular processes. We suggest that inhibition of AP-1 could be a new therapeutic 
strategy for treatment of breast cancer, especially TNBC. 
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1 INTRODUCTION 
1.1 Activator Protein-1 
AP-1 (activator protein-1) as a transcription factor is a dimeric complex. It was originally 
characterized in early 1987 (1). Mammalian AP-1 proteins are composed of multiple 
members of the Jun (c-Jun, JunB, and JunD), Fos (c-Fos, FosB, Fra1 and Fra2), ATF (ATF2, 
LRF1/ATF3, B-ATF, JDP1, JDP2) and MAF (c-Maf, MafA, MafB, MafG/F/K and Nrl) 
subfamilies (2, 3).  
 
 
Figure 1. AP-1 structure. (A) The location of bZIP domain in Jun and Fos family members. (B) The AP-1 
complex binds to DNA as homo- or heterodimers through the bZIP domain. Numbers represent amino acids 
from the amino to the carboxy termini.  
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AP-1 proteins dimerize and bind to DNA through the bZIP (basic leucine zipper) DNA 
binding domain which is composed of leucine zipper and basic regions (4, 5) (Figure 1). In 
the Jun family, due to a lower degree of conservation of the amino-terminal region from 
amino acids 1 to 95, 3 members of Jun protein are described although they share a high 
degree of sequence homology (6, 7). Compared to homodimerized Jun proteins, Fos-Jun 
heterodimers form more stable dimers when binding to TPA (12-O-tetradecanoylhporbol-13-
acetate) response elements (TRE, 5’-TGAC/GTCA-3’). Fos family members do not 
homodimerize (8, 9). Unlike Jun-Jun and Jun-Fos dimers, the Jun-ATF heterodimer bind to 
another consensus sequence, the cAMP-responsive element (CRE, 5’-TGACGTCA-3’) (10). 
Various Fos-Jun dimers are present not only in different cell types under different conditions, 
but also in different cell cycle stages (11-13). For example, after serum stimulation in mouse 
fibroblasts, initially c-Fos and FosB form heterodimers with c-Jun and JunB during the G0-to-
G1 transition , then Fra1 and Fra2 are the predominant Fos proteins to form heterodimers with 
all members of Jun proteins during exponential growth (12). It has been reported that more 
than 50 different proteins interact with Fos-Jun family members and contribute to AP-1 
functions (14). As shown in Figure 2, there are three different models of other proteins 
interacting with Fos-Jun proteins, 1) by bZIP domain, such as, NF-E2 (Nuclear Factor, 
Erythroid 2) family members (15); 2) by binding to regulatory elements adjacent to AP-1 sites 
(TGAGTCA) directly, such as NFAT (Nuclear factor of activated T-cells) protein; 3) by 
binding to regulatory elements adjacent to AP-1 sites indirectly, such as Smad family 
members which need to interact with other factors to bind the DNA (16, 17). 
 
Figure 2. Models of Fos-Jun interactions with other proteins. A. Via the bZIP domain. B. By direct binding 
to regulatory elements adjacent to AP-1 sites. C. By indirect binding to regulatory elements adjacent to AP-1 
sites. TGAGTCA: AP-1 site.  
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1.1.1 Jun family 
The Jun family consists of c-Jun, JunB and JunD. The JunB and JunD genes are located on 
chromosome 19, and the c-Jun gene is located on chromosome 1. It was reported that Jun 
family members are highly expressed and play an important role in different tumor types such 
as non-small-cell lung cancer, prostate cancer, breast cancer, colorectal adenocarcinoma and 
acute myeloid leukemia (18-22). It is well known that c-Jun can promote cell proliferation, 
survival and apoptosis. In contrast, JunB and JunD have been shown to act as tumor 
repressors in some studies (23-25).  
N-terminal phosphorylation of c-Jun is crucial for its activation and is triggered by post-
translational modifications mainly controlled by JNKs (Jun N-terminal kinases), such as ERK 
(extracellular-signal-regulated kinase) and p38 isoforms (7). JNK phosphorylates Ser63, 
Ser73, Thr91 and Thr93 of the c-Jun protein, increasing the stability, DNA binding and 
transactivation potential of c-Jun (Figure 3). Other transcription factors such as SP1 
(specificity protein 1), NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
and MEF2 (myocyte enhancer factor-2) can induce the transcription of c-Jun and increase its 
mRNA stability resulting in increased levels of c-Jun (26). Subsequently, c-Jun induces rapid 
stimulation of genes involved in promoting the cell cycle such as cyclin D1 or repression of 
negative regulators of the cell cycle such as the tumor suppressor p53 (27, 28). 
 
 
Figure 3. c-Jun protein domain structure and phosphorylation sites. S, serine. T, threonine.  
Unlike c-Jun, JunB lacks phosphor-acceptor residues and JunD lacks an effective JNK 
docking site and subsequently they are weak phosphorylation substrates of JNK. However, 
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MAPK/ERK can phosphorylate JunD, making the transcriptional activity of JunD stronger 
than that of JunB (29). Normally, JunB and JunD are considered as tumor suppressor genes 
(23, 30). However, in the absence of c-Jun, JunB has been demonstrated to exhibit 
proliferative effects by inhibiting the expression of p53 in mice (31). 
1.1.2 Fos family 
The Fos family consists of c-Fos, FosB, Fra1 and Fra2, the corresponding genes of which are 
located on chromosome 14, chromosome 19, chromosome 11 and chromosome 2, 
respectively. c-Fos and FosB harbor a strong transactivation domain in their C-terminal part, 
which Fra1 and Fra2 do not have (32). Subsequently, Fra1 and Fra2 transactivation potencies 
are weaker than the corresponding activities of c-Fos and FosB. In contrast to Jun family 
members which can form homodimers, Fos family members have to form heterodimers with 
Jun or ATF family members to regulate gene expression. 
Fos proteins are widely expressed in various tumors, including bone tumors (33, 34), 
endometrial carcinoma (35, 36), cervical cancer (37, 38), ovarian cancer (39, 40), 
mesotheliomas (41, 42), lung cancer (43, 44), colorectal cancer (45, 46), skin tumors (47, 48), 
melanomas (49, 50), thyroid carcinomas (51, 52), esophageal cancer (53, 54), hepatocellular 
carcinomas (55, 56) and breast cancer (57, 58). As shown in Figure 4, the activation of c-Fos 
can occur due to phosphorylation by ERK at T325, T331 and S374, also by RSK1 (ribosomal 
s6 kinase1) and RSK2 at S362 (59). In addition, ultraviolet light can activate c-Fos by 
phosphorylation at T232, T325 and T331 via p38/MAPK kinases (60). Stabilization of c-Fos 
relies on ERK-mediated phosphorylation, while Fra1 stabilization also relies on ERK-
mediated phosphorylation but at different sites (59).  
 
Figure 4. c-Fos protein domain structure and phosphorylation sites.  
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1.1.3 AP-1 signaling pathways 
AP-1 activity is induced by complex networks of signaling pathways that involve several 
physiological stimuli and environmental insults, such as growth factors, cytokines, UV 
irradiation and viral infections (61, 62).  
As shown in Figure 5, growth factor stimulation activates PI3K/AKT and ERK, the latter 
which is the subgroup of MAPKs pathways that enhance AP-1 activity (63). The ERK 
subgroup can directly phosphorylate Fra1 and Fra2 and enhance their DNA binding activity 
when in complex with c-Jun (64). In addition, Fra1 and c-Jun are mainly induced by activated 
Ras signaling pathways compared to other AP-1 family members (65). TNFα and cytokines 
potently induce AP-1 through activating JNK signaling which can phosphorylate AP-1 and 
thereby enhance its transcriptional activity (66). Once AP-1 is activated, it is able to regulate 
its targeted genes, leading to regulation of proliferation, apoptosis, inflammation, invasion 
and EMT (Epithelial-to-Mesenchymal Transition). 
         
      
Figure 5. Signaling pathways up-stream of AP-1  
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1.2 AP-1 function 
AP-1 plays an important role in a wide range of physiological and pathological cellular 
processes from cell proliferation and development to invasion, apoptosis and EMT. Although 
all AP-1 members contain the bZIP domain, the individual proteins have different effects in 
different kinds of cell types. These diverse functions are due to differential dimerization of 
AP-1 family members which alter the promoter binding, transcriptional capacity, protein 
stability and localization of AP-1 complexes (67-69).  
The AP-1 transcription complex is often considered as an oncoprotein (1). However, whether 
AP-1 is oncogenic or anti-oncogenic not only depends on the differential dimerization 
between AP-1 family members, but also depends on the tumor types, tumor stages and the 
genetic background of tumors. For example, it has been shown that JunB acts as a tumor 
suppressor for development of chronic myeloid leukemia (70). In contrast, JunB promotes cell 
invasion and angiogenesis in VHL (von Hippel-Lindau) -defective clear-cell renal-cell 
carcinoma (71). 
1.2.1 Cell proliferation 
Among AP-1 family members, c-Jun has been reported in several studies that it acts primarily 
as a positive regulator of cancer cell proliferation, such as in classical Hodgkin lymphoma, 
glioblastoma and breast cancer (72-74). c-Jun protein has been demonstrated to be activated 
by phosphorylation via JNK signaling, inhibiting the expression of p53 or inducing cyclin D1 
expression to promote cell proliferation (75, 76). In addition, c-Jun is required for liver 
regeneration in vitro (28). 
Unlike c-Jun, JunB and JunD attribute mainly to anti-proliferative effects in most studied 
systems. JunD inhibits the cell proliferation of intestinal epithelial cells and fibroblasts (30, 
77). Overexpression of JunB inhibits malignant skin cell proliferation in vivo and in vitro (78). 
However, it has been described that not only JunB and JunD, but also c-Jun has anti-
proliferative function, such as in fibroblasts and multiple myeloma (79, 80). c-Jun has been 
shown to exert also an anti-proliferative function in osteoclasts when dimerized with c-Fos 
(81). Additionally, the expression of JunB and JunD may be positively correlated with cell 
proliferation in diffuse large B-cell lymphomas (82). 
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For the Fos family, high expression of FosB is negatively correlated with p16 which is a 
tumor suppressor protein. This might contribute to an important role of FosB in regulating 
normal proliferation and differentiation of mammary epithelial cells (83). Inhibiting the 
expression of Fra1 induces a tumor supportive set of secreted signals in melanoma cells in 
vivo and in vitro (84). c-Fos contributes to promote cell proliferation through ERK1/2 
signaling pathways in primary rat hepatic stellate cells (85). Fra2 can stimulate cell growth by 
forming heterodimers with JunD in adult T-cell leukemia cells (86). 
Other AP-1 family members also have their pivotal roles in cell proliferation. c-Maf can 
promote myeloma proliferation by activating the cyclin D2 promoter (87). For the ATF 
family, ATF-2 can activate cell proliferation (88), whereas another ATF family member, B-
ATF, is considered as a tumor suppressor gene (89). 
1.2.2 Apoptosis and survival 
The pro-apoptotic or anti-apoptotic functions of AP-1 are not only dependent on specific cell 
type, but are also dependent on heterodimerization between different AP-1 members and the 
type of external or internal stimuli.  
Overexpression of c-Jun has been shown to induce apoptosis in multiple myeloma cells, 
esophageal adenocarcinoma and endothelial cells (79, 90, 91). c-Jun and c-Fos are required to 
promote inflammation and cell death in skin tissue (92). c-Fos also has a pro-apoptotic 
function in prostate cancer cells upon TNF–related apoptosis-inducing ligand (TRAIL) 
stimulation (93). However, under cisplatin treatment, c-Fos plays an anti-apoptotic role in 
thyroid cancer (94). Combination of ATF3 and c-Jun expression can promote survival in 
neurons during injury (95).  
1.2.3 Invasion and metastasis 
EMT is one of the hallmarks of invasion and metastasis. It is a process by which epithelial 
cells lose their cell polarity and cell-cell adhesion to become mesenchymal stem cells. 
Extensive evidence suggests that AP-1 may be a key mediator to regulate gene expression in 
relation to EMT. For example, AP-1 directly regulates invasion effector genes, such as MMP9 
(matrix metallopeptidase 9) and CD44, or invasion suppressor genes, such as fibronectin and 
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STAT6 (signal transducer and activator of transcription 6) in vitro and in vivo. In addition, 
AP-1 can regulate cell invasion by interacting with other transcription factors, such as NFκB 
and Ets in a variety of human tumor cells (96). 
In recent years, it has been reported that c-Jun and Fos proteins contribute to TGF-β1-induced 
EMT in breast cancer, but not JunD and FosB (97, 98). Mitochondrial dysfunction which 
induces EMT is dependent on c-Jun activation (99). In colorectal cancers, c-Jun and ATF-2 
but not c-Fos are required for Twist1-induced EMT by phosphorylation via JNK (100). 
1.2.4 Angiogenesis 
A direct role for c-Jun in angiogenesis through VEGF (vascular endothelial growth factor)-
induced neovascularization was identified in rodents in 2004 (101). Later, a correlation 
between c-Jun activation and angiogenesis was confirmed in breast cancer patients (72). JunB 
promotes angiogenesis through regulating the expression of MMP9 and MMP2 in VHL (Von 
Hippel-Lindau)-defective renal cell carcinoma (71). In addition, increased c-Fos and c-Jun 
heterodimer formation and DNA binding lead to lymphangiogenesis upon IL7 (Interleukin 7) 
stimulation in lung cancer (102). The expression of Fra1 is also necessary for angiogenesis in 
vitro and in vivo (103). 
1.2.5 AP-1 in mouse development 
Different Jun and Fos knock-out mice models exhibit various phenotypes (104). Fra1, c-Jun 
or JunB knock-out in mice present with an embryonic lethality phenotype and mice die 
around day 10 (105-107). Mice lacking Fra1 have defects in the placenta and the yolk sac, 
while mice lacking c-Jun have defects in the heart and the liver. Lack of JunB not only causes 
defects in the placenta and the yolk sac, but also vascular defects in extra-embryonic tissues. 
Mice lacking c-Fos, FosB, Fra2 or JunD can develop normally. However, inactivation of c-
Fos leads to osteopetrosis and the null c-Fos mice have more wakefulness (108, 109). 
Inactivation of FosB leads to nurturing defects due to changes in the hypothalamus region 
(110). Inactivation of JunD leads to sterility and age-related endothelial dysfunction in male. 
Inactivation of Fra2 leads to defects in chondrocytes and osteoclasts in newborn mice (104, 
111, 112).   
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1.3 Breast cancer 
Breast cancer is the most common female cancer worldwide, and the incidence is about 100 
times higher in women compared to men. Of all types of cancer, 25% of them are breast 
cancer, and breast cancer is strongly related to age. In African-American women, breast 
cancer is more common in women who are under 45 years of age and they have a higher risk 
to die. Some risk factors for breast cancer have been identified, such as genetic predisposition 
(particularly BRCA1 and BRCA2 mutations), family history, taking hormones and older age 
at first birth or never having given birth. However, most of the patients do not present with 
specific risk factors. In the whole world, 21% of deaths in breast cancer are associated with 
obesity, high intake of alcoholic beverages and lack of physical activity (113-116).  
1.3.1 Breast cancer molecular subtypes 
Breast cancer can be classified according to histopathology, stage and histological grade. 
However, these classifications do not give detailed biological characteristics of the tumors 
that have similar clinical and pathological presentations. Therefore, global gene expression 
microarray studies that classify breast cancer into distinct biological classes based on gene 
expression patterns have opened a broad field in cancer research regarding breast cancer 
initiation, development and identification of potential new therapy targets. 
Gene expression profiles classify breast cancer into five intrinsic molecular subtypes, 
including luminal A and B, HER2-positive, basal-like and normal breast-like (117). 
Immunohistochemical (IHC) staining classifies the breast cancer into three molecular 
subtypes: ER-positive, HER2-positive and triple-negative. Clinically, substantial numbers of 
TNBC (triple-negative breast cancer) are basal-like subtype. However, the discordance 
between the gene-based and immunohistochemical-based profiles is considerable (118, 119) 
(Table 1).  
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Table 1. Molecular subtypes of breast cancer 
Intrinsic subtypes (%) IHC ER PR HER2 Other markers Therapy 
Luminal 
(75%) 
Luminal-A 
(50%-60%) 
Luminal-A + + - Low Ki67 
 Endocrine therapy 
for the majority of 
cases 
 Chemotherapy is 
considered in case 
of high tumor 
burden or grade 3 
Luminal-B 
(15%-20%) 
Luminal-B + +/- +/- 
 High Ki67 
 High expression of 
proliferation-
related genes 
compared with 
Luminal-A 
 Endocrine therapy 
+ Chemotherapy 
for the majority of 
cases 
 Endocrine therapy 
+ Chemotherapy + 
Anti-HER2 for 
HER2-positive 
HER2-
positive 
(15%-20%) 
 
HER2-
positive 
- - + 
Other genes associated 
with the HER2 pathway 
Chemotherapy + Anti-
HER2 
Basal-like 
Classic 
basal-like 
(8%-37%) 
Triple-
negative 
- - - 
 High levels of 
basal myoepithelial 
markers 
 Overexpress P-
cadherin,fascin,cav
eolins1 and 2, 
alpha-beta 
crystalline and 
EGFR 
Chemotherapy 
Claudin-low 
(7%-14%) 
Triple-
negative 
- - - 
 Low expression of 
claudins 3,4 and 7 
 Enrichment for 
EMT markers 
Chemotherapy 
Normal breast-
like 
(5%-10%) 
 
Triple-
negative 
- - - 
 CK5- 
 EGFR- 
Chemotherapy 
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Approximately 75% of breast cancers are of the luminal subtype which can be further divided 
into luminal A and luminal B based on expression of Ki67 (120). Luminal A is the most 
common subtype. Patients with luminal A have good outcomes with hormonal therapy, and 
have low expression of Ki67 compared with Luminal B. Due to the high expression of 
proliferation-related genes, such as GGH (gamma glutamyl hydrolase), NSEP1 (nuclease 
sensitive element binding protein 1) and CCNE1 (cyclin E1) or genes associated with 
alternative growth factor pathways, such as FGFR1 (fibroblast growth factor receptor 1), 
HER1 and Src (sarcoma proto-oncogene), Luminal B is insensitive to endocrine therapy and 
responds better to adjuvant chemotherapy (118). HER2-positive and basal-like subtypes are 
high-risk tumors, and both of them have poorer outcomes. However, whereas the HER2-
positive subtype of breast cancer can be treated by targeting HER2, basal-like tumors 
characterized by the absence of ER, PR and HER2 expression have worse prognosis (121). 
Claudin-low type that is described as a kind of basal-like breast cancer identified by low 
expression of claudins 3, 4 and 7 has very poor prognosis and a great degree of chemotherapy 
resistance (122). Although normal breast-like tumors lack expression of ER, PR and HER2, 
they are not considered to be basal-like subtype due to the absence of CK5 and EGFR 
expression, and they present with an intermediate prognosis between luminal and basal-like 
subtypes (118).  
1.3.2 Triple negative breast cancer 
Of all breast cancer tumors, about 10-20% are TNBC. Compared with non-TNBC, TNBC 
tumors are more aggressive and have a higher proliferation rate. Due to the lack of targeted 
therapies, chemotherapy is the systemic therapy currently available. Patients with TNBC 
experience often relapse more quickly and have worse prognosis compared to the other 
subtypes (123). 
In order to further determine the biomarkers of TNBC subtypes, six different TNBC subtypes 
are identified based on gene expression profiles, including BL1 and BL2 (basal-like 1 and 2), 
IM (immunomodulatory), M (mesenchymal), MSL (mesenchymal stem-like) and LAR 
(luminal androgen receptor) subtypes (124, 125). More recent advances overlapping these six 
TNBC subtypes with the classification of intrinsic breast cancer subtypes provide five new 
molecular subtypes of TNBC: BL-TNBC (basal-like TNBC), ML-TNBC (mesenchymal-like 
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TNBC), I-TNBC (immune-associated TNBC), LA-TNBC (luminal/apocrine TNBC) and 
HER2e-TNBC (HER2-enriched TNBC) (126) (Table 2).  
Table 2. Subtypes of TNBC 
Whole-genome gene expression profiling  
Subtype High expression 
BL1 Ki67, cell division and DNA damage response pathways 
BL2 Ki67, proliferation-associated, DNA repair genes and growth factor signaling 
IM Immune cell processes and immune signal transduction pathways 
M PI3K and Wnt pathways 
MSL PI3K, Wnt pathways and mesenchymal stem cell-associated genes 
LAR Steroid synthesis and androgen/oestrogen metabolism, such as AR 
Overlapping with intrinsic breast cancer subtypes  
Subtype characteristic 
BL-TNBC DNA-repair deficiency, growth factor pathway expression 
ML-TNBC EMT and cancer stem cell features 
I-TNBC Immune-associated  
LA-TNBC Androgen receptor overexpression 
HER2e-TNBC HER2-enriched 
 
With this, multiple potential therapeutic targets for TNBC have been identified, such as AR 
(androgen receptor), EGFR (epidermal growth factor receptors), Bcl2 family members, 
BRCA family members, adhesion molecules and p53 (127, 128). 
1.3.3 Estrogen signaling and breast cancer 
ERs belong to the nuclear receptor superfamily of ligand-activated transcription factors and 
have two isoforms (ERα and ERβ). Both of these two isoforms consist of a DNA-binding 
domain, a ligand-binding domain, and two transcriptional activation function domains. They 
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share a 56% homology in the ligand-binding domain. However, partly due to a lack of highly 
efficient and selective anti-ERβ antibodies to quantify ERβ protein levels, the function of ERα 
is more clearly defined. ERα, as a hallmark of hormone-dependent tumor growth, is linked to 
prognosis and response to endocrine therapy (129). It has been reported that ERβ could be 
expressed in ER-positive breast cancer tumors and play a role as a tumor suppressor gene and 
may increase the sensitivity of ER-positive breast cancer tumors to tamoxifen (130, 131). In 
recent years, it has been reported that the variants of ERβ play different roles in TNBC (128).  
 
 
Figure 6. ER signaling pathways. Pathway 1. ER binds to specific estrogen response elements of target genes 
to activate gene expression. Pathway 2. ER regulates gene expression through interaction with other transcription 
factors. Pathway 3. ER and its co-factors modulate gene expression subsequent to phosphorylation via growth 
factor receptor signaling pathways. Pathway 4. This is a non-genomic pathway where membrane-localized ER 
regulates gene expression without binding to DNA directly.  
Estrogen signaling can be broadly classified into genomic or non-genomic pathways (Figure 
6). The classical genomic pathway of ER signaling infers that ER regulates gene expression 
through binding to specific estrogen response elements after that it has formed a dimer upon 
binding of E2 (17β-estradiol) (Pathway 1). ER also modulates gene expression by interacting 
with other transcription factors, such as AP-1, Sp1, NFκB, and RUNX1 (Pathway 2) (129). 
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Furthermore, ER can regulate target gene expression in a ligand-independent manner in which 
ER binds DNA directly or indirectly following ER activation through phosphorylation by 
protein kinases, including PI3K and MAPK kinases (Pathway 3). Finally, in the non-genomic 
pathway, membrane-localized ER can elicit rapid responses to E2 involving activation of the 
PI3K/MAPK signaling pathway, and thereby stimulate cell survival and proliferation without 
binding directly to DNA (Pathway 4) (129, 132).  
1.3.4 AP-1 and breast cancer 
Since AP-1 was identified as a transcription factor in 1987, the function of AP-1 has been 
broadly studied but not so much in breast cancer (Figure 7). It has been shown that AP-1, as a 
mediator of signal transduction, plays an important role in regulating cell proliferation, 
invasion and progression of breast cancer. AP-1 blockade in established breast tumors 
suppresses their growth in nude mice (133). 
 
 
 
Figure 7. Number of papers published between 1987 and 2014 according to a recent PubMed search using 
“AP-1 in breast cancer” and “AP-1”. 
It is clear that AP-1 is involved in ER signaling pathways to modulate gene expression in 
ERα-positive breast cancer. Several studies have found that c-Fos is required for cell 
proliferation in breast tumors (134). Up-regulation of AP-1 is associated with tamoxifen 
resistance and increased invasiveness of MCF7 breast cancer cells and ERα-positive breast 
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tumors (135-137). Recently, it was reported that Fra1 expression is correlated with poor 
prognosis, corresponding to shorter overall survival and higher rate of lung metastasis, in ER-
positive breast cancer patients (138). Furthermore,  AP-1 family members, c-Fos and c-Jun, 
are involved in TGFβ1-mediated EMT in MCF7 cells (139). 
There have not been many studies about the function of AP-1 in TNBC. It has been reported 
that compared to ER-positive breast cancer, Fra-1 is overexpressed and involved in cell 
proliferation, invasion and migration in ER-negative breast cancer cells (140). However, the 
mechanistic aspects of the modulatory effect of AP-1 in breast cancer, especially in TNBC are 
still unclear. 
1.3.5 Therapeutic treatment of breast cancer 
Surgery, radiation therapy, chemotherapy, endocrine therapy and targeted therapy are 
treatments of breast cancer (141). Radiation therapy is used to ensure that all the cancer cells 
are killed after surgery, and can shrink tumors in combination with chemotherapy. Endocrine 
therapy, such as the ER antagonist tamoxifen blocks the activity of ER in ER-positive breast 
cancer. An example of targeted therapy is trastuzumab that is a humanized anti-HER2 
monoclonal antibody used for HER2-positive breast cancer tumors. Chemotherapy is used in 
the majority of ER-negative breast cancer patients, especially TNBC cases (142). However, 
chemotherapy can lead to hair loss, suppressed immune system and other serious negative 
side effects. Altogether, the above necessitates the identification of novel therapeutic 
strategies for TNBC patients. 
1.4 Targeting transcription factors for cancer therapy 
During tumorigenesis, some transcription factors are wrongly modulated by cellular pathways 
to overexpress or repress target genes and subsequently drive cancer cell biology. Thus, 
targeting transcription factors is a possible strategy for cancer therapy. Many transcription 
factors have been identified as potential therapeutic targets for cancer treatment, such as 
NFκB, STAT3, Notch, ATF5, HOX and AP-1 (143). 
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There are several ways to target transcription factors, including directly targeting the 
transcription factor; blocking protein-DNA or protein-protein interactions; destabilization of 
the mRNA of these transcription factors using siRNA (small interfering RNA) or antisense 
oligonucleotides; alteration of the functions and gene expression patterns of transcription 
factors using enzymatic regulators (144) (Table 3).  
Table 3. Examples of mechanisms to target transcription factors 
Mechanism Example Transcription factor Disease 
Direct target Tamoxifen ER Breast cancer 
Protein-protein 
interactions 
ABT-199 BCL2 Chronic lymphocytic leukaemia 
Protein-DNA 
interactions 
T-5224 AP-1 Arthritis 
RNA degradation AZD9150 STAT3 Lymphoma 
Enzymatic regulator Ruxolitinib STAT proteins Myoproliferative neoplasms 
 
However, unlike kinases that have fairly good drugable surfaces or cavities for binding of 
small molecules that alter their activity, transcription factors are more difficult to target due to 
the large surfaces for DNA and protein interactions. Additionally, their nuclear localization 
makes access of therapeutic agents more difficult. 
1.5 Inflammation and cancer 
In tissue microenvironments, leukocytes including neutrophils, monocytes and eosinophils 
will be activated and directly migrate from the venous system to sites of tissue injury to 
activate a multifactorial network of chemical signals and thereby cause inflammation for 
healing the injured area.  
Neutrophils are the first recruited effectors after that the acute inflammatory response is 
activated. Macrophages are then activated and become the main source of cytokines which 
can cause acute inflammation that can develop into chronic inflammation (145). In the last 
decades, chronic inflammation has been identified as an inducer of various cancers (146). 
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Chronic inflammation induces alterations of both epithelial and stromal elements that in turn 
can lead to tumor initiation and tumor cell growth (Figure 8). 
 
Figure 8. Chronic inflammation microenvironment. After tissue injury or infection, both epithelial and 
stromal cells are prone to mutagenesis and hyperplasia. Cytokines which are mainly released from macrophages 
may cause chronic inflammation, than further promote tumor cell hyperplasia and activation of 
neovascularization. 
The relationship between inflammation and development of cancer is complex. Cytokines, 
such as TGF-β, play a role as tumor suppressors in early stages of tumor microenvironment 
(147). In contrast, exposure to pro-inflammatory cytokines, such as IL-6, IL-8 and TNFα 
(tumor necrosis factor α), transforms cells into a malignant career with changes resulting in  
cell proliferation and invasion (148).  
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1.5.1 TNFα 
TNFα was discovered in 1975 (149). The human TNFα gene was cloned in 1985 (150). TNFα 
is an inflammatory cytokine that is mainly produced by macrophages, but also by a variety of 
other cell types such as NK cells, CD4+ lymphocytes, neutrophils, mast cells, and neurons 
(145). 
In the tumor microenvironment, TNFα induces cell survival, EMT and further increases the 
expression of TNFα itself and other cytokines by the malignant cells (151). Interestingly, 
high-doses of TNFα, locally administered in breast cancer, show anti-angiogenic and anti-
tumor effects (152). However, irrespective of whether the function of TNFα is pro-tumor or 
anti-tumor, there is no doubt that TNFα plays an important role in cancer. 
1.5.2 TNFα signaling 
TNFα exerts its biological functions by binding to its two receptors: TNF receptor 1 (TNFR1) 
and TNF receptor 2 (TNFR2). TNFR1 is expressed broadly in most cell types. TNFR1 can be 
fully activated by soluble and membrane-bound forms of TNFα. TNFR2 is only expressed in 
the immune system and is activated only by membrane-bound forms of TNFα. As opposed to 
TNFR1, TNFR2 plays mainly pro-survival functions as it does not have the death domain 
which TNFR1 has. However, if the cells have TNFR1 and TNFR2 co-expression, under 
certain conditions, such as under stress, TNFR2 may shift to TNFR1 signaling which can lead 
to apoptosis (153, 154). 
As shown in Figure 9, after TNFα ligand binding to TNFR1 or TNFR2, TNFR-associated via 
the death domain (TRADD) can be recruited to TNFR1 or TNFR2, which in turn activates 
NFκB, p38-MAPK and JNK signaling pathways to regulate cell survival, proliferation and 
inflammation. In general, TNFα induces apoptosis through activating caspase cascades or 
JNK signaling pathways (151). However, when NFκB signaling is activated via IκB kinases 
( IKK) complex which can be induced by both receptor-interacting protein (RIP) and TNF 
receptor-associated factor 2 (TRAF2) (155), the negative regulators of apoptosis such as 
cellular FLICE-like inhibitory protein (cFLAR), also known as FLIPL, BCL2 and superoxide 
dismutase will be induced that, in turn, interfere with apoptosis (66, 153).  
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Figure 9. TNFα signaling pathways. TNFR1 and TNFR2 are activated by ligand-binding through memTNF or 
sTNF.TNFR1signalling triggers two different events. One is to stimulate caspase cascade signaling resulting in 
apoptosis. The other one is to induce JNK, p38-MAPK and NFκB signaling pathway that can result in cell 
survival, proliferation and inflammation. In addition, NFκB activation induces negative regulators of apoptosis 
that, in turn, inhibit apoptosis. Normally, TNFR2 stimulates pro-survival functions. When co-expressed with 
TNFR1 and under certain conditions such as under stress, TNFR2 can shift to TNFR1 signaling via recruitment 
of TRADD. memTNF, membrane-bound TNF; sTNF, soluble TNF; TRADD, TNFR-associated via death 
domain; FADD, FAS-associated via death domain; RIP, receptor interacting protein; TRAF2, TNF-receptor-
associated factor.  
1.6 Genome-wide studies of AP-1 
Genome-wide study is to study transcription at a genomic scale, also referred to as 
transcriptomics. It relies on data from microarrays or high throughput sequencing (HTS) 
which allows rapid decoding of millions of DNA fragments at the same time. In addition, 
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HTS’s low cost combined with high efficiency has led it to become a very popular method 
with applications in different areas of science. 
Microarray technology has been widely used since the late 1990s (156, 157), and applied to 
cancer research since the 2000s. DNA microarray, one of the microarray technologies, has 
become an easy and rapid way to identify tumor-specific molecular markers for prognosis or 
potential therapy targets for cancer due to its relatively low cost (158-160).  
ChIP (chromatin immunoprecipitation) technique was developed by Gilmour DS and Lis JT 
in 1980s (161-164). ChIP has become an important experimental technique to detect DNA-
protein interactions and their specific genomic localization in the cells (Figure 10). ChIP-seq 
is ChIP assay combined with HTS. ChIP-seq can be used to map transcription factor binding 
sites and discover their networks (165, 166). Also, ChIP-seq can be used to discover distinct 
mechanisms underlying the transcription factor-mediated differential gene regulations (167). 
In addition, ChIP-seq is a useful technique to discover histone marks (168).   
            
Figure 10. Principle of ChIP assay. DNA-protein complexes are crosslinked by formaldehyde. After that, the 
samples are sonicated into 200-1000bp fragments. By immunoprecipitation with specific antibodies, target 
protein-DNA complexes are pulled-down. DNA is ready to be analyzed after reverse crosslinking and further 
purification. 
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The development of microarray and ChIP-seq technologies provided researchers with high-
throughput genomic tool to gain new insights into interactions between transcription factors 
and their regulatory networks. Using DNA microarrays, JunB and JunD were identified to be 
crucial for pathogenesis of primary cutaneous T-cell lymphomas (169, 170). By ChIP-seq 
analyses, Simon C et.al confirmed that AP-1 is critical for glucocorticoid receptor (GR) 
binding and its recruitment to co-occupied regulatory elements in a murine mammary 
epithelial cell line (171). In MDA-MB-231 breast cancer cells, Yes-associated 
protein/Tafazzin (YAP/TAZ), which does not carry a DNA-binding domain, need TEA 
domain family member (TEAD) factors co-occupying chromatin with AP-1 bound to 
composite regulatory elements to regulate gene transcription and to drive oncogenic growth 
(172). Combining ChIP-seq and microarray assay together, the direct target genes of JunD/c-
Jun and JunD/ATF were identified in a rat model of crescentic glomerulonephritis (173). 
Considering the important role of AP-1 in breast cancer as discussed above, a better and more 
highly understanding of molecular mechanisms of AP-1 signaling should provide important 
information that can potentially be explored to develop new therapies. Thus, exploring the 
genome-wide impact of transcription factor AP-1 in breast cancer is crucial. 
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2 AIMS OF THE THESIS 
The overall aim of this project was to explore the genome-wide transcriptional regulatory 
networks of the transcription factor AP-1 in breast cancer cells with the ultimate hope that this 
knowledge will lead to novel strategies to develop candidate therapies for breast cancer 
patients in the future. In particular, the four specific aims were: 
I. To address the role of AP-1 in gene expression programs including those controlled by 
estrogen-activated ERα. 
II. To gain a genome-wide map of AP-1 binding and investigate mechanisms underlying 
AP-1-mediated gene regulation in TNBC cells. 
III. To dissect the AP-1 – ZEB2 axis in TNFα-induced EMT in TNBC cells. 
IV. To explore genome-wide analysis of AP-1 regulation of transcriptional programs in 
TNFα-stimulated TNBC cells. 
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3 METHODOLOGICAL CONSIDERATIONS 
Significant considerations and limitations of the major methods used in this thesis are 
discussed below. 
3.1 Cell lines 
There are 16 different breast cancer cell lines used in this thesis. T47D, MCF7, MDAMB175, 
ZR751, SKBR3, HCC1569, MDAMB453, HCC202, HCC1954, MDAMB231, BT549, 
Hs578T, Sum159 and MDAMB157 cells were purchased from the American Type Culture 
Collection (ATCC). Whole-cell lysates of MDAMB361 and HCC70 which were used in 
paper II were obtained from Biomiga. The 16 different breast cancer cell lines can be 
classified into 3 groups: an ER-positive group, a HER2-positive group and a triple-negative 
group (no ER, PR and HER2 expression) based on gene expression profiles (174, 175). 
Cell lines can be cultured infinitely, be easy to grow, are useful models and widely used for 
breast cancer research. However, results derived from the same subtypes are not exactly the 
same, even results from the same cell line studied in different labs can be different. That is 
because the origin of cells is different which leads to distinct signaling networks, although 
they are classified into the same subtypes based on gene expression. The culture conditions 
and passage numbers of the same cell line can also influence results in different labs (176). 
In this thesis, we choose BT549 as an in vitro model for TNBC due to its high expression of 
AP-1 and that it is easier to transfect compared to other TNBC cell lines, such as 
MDAMB231 and Hs578T. 
3.2 Quantitative polymerase chain reaction 
Quantitative real time polymerase chain reaction (RT-PCR, qPCR) is widely used to measure 
gene expression. Two methods are common. In one, the SYBR Green dye which binds the 
minor groove of double-stranded DNA is used to quantitate the production of PCR products. 
Thus, if nonspecific products or primer-dimers are present in the SYBR Green dye assay, it 
will generate false positive signals. The other, TaqMan uses a fluorogenic single-stranded 
oligonucleotide probe which contains a fluorescent reporter dye at the 5’ end of the probe and 
a quencher dye at the 3’ end of the probe, to quantitate the production of PCR products. Only 
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specific PCR product can generate a fluorescent signal in TaqMan qPCR. Therefore, 
compared to SYBR Green dye based method, the TaqMan probe assay is more sensitive but 
generates lower calculated expression levels (177). However, there is no intrinsic reason that 
TaqMan probe assay would be required over SYBR Green dye assay. We have mainly used 
the SYBR Green dye assay in this thesis due to its lower cost. In addition, we have checked 
the PCR efficiency, confirmed that the SYBR Green dye assay amplified a single product 
using a denaturation curve and obtained the similar results as TaqMan probe assay. 
3.3 Gene expression microarray analysis 
High-throughput gene expression approaches such as microarrays and RNA-sequencing 
(RNA-seq) are able to measure expression of thousand genes in one sample and provide 
global out-look on complex biological processes at the same time. Based on massive parallel 
DNA sequencing technology, RNA-seq is a powerful method for research in discovering, 
profiling, and quantifying RNA transcripts. Despite the rapid advance in RNA-seq approaches, 
microarrays still remain the most popular and widely used techniques for whole genome 
expression profiles, especially in humans.  
In this thesis, we used two technologies, Agilent SurePrint G3 Human GE 8x60K array which 
is ink-jet technology and Affymetrix human Gene 1.1 ST array which is photolithography 
technology, to study global gene expression. Agilent arrays have 60mers oligonucleotides 
which are longer than those used in the Affymetrix arrays (25mers), but lower density arrays 
than Affymetrix. The Affymetrix platform is the earliest technology used in studies of global 
gene expression and has been used since 1989 and it remains widely used. Compared to other 
gene expression arrays, Affymetrix has a rich bioinformatics architecture that allows for a 
broad range of analyses that provide more clues for the further study. 
A higher cutoff for fold change will decrease the sensitivity but increase the specificity. In 
contrast, a lower cutoff fold will increase the sensitivity but decrease the specificity. In order 
to have good sensitivity and specificity of the analysss, we applied a cutoff fold of 2.0 or 1.5 
and p-value less than 0.05 for significantly modulated gene expression. 
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3.4 Chromatin immunoprecipitation (ChIP) 
ChIP is a powerful tool and a direct way to identify DNA-protein interactions and their 
specific genomic localization in living cells. Good and clear ChIP results are dependent on 
cell numbers, the range of chromatin fragments after sonication and the specificity of the 
antibody in this particular. However, tissue and cell specific effects also influence the results. 
Data might not be the same for different cell lines, even though they belong to the same 
subtype. Due to the dynamics of cells, samples collected at different time points may show 
various intensities of signals.  
3.5 Small interfering RNA (siRNA) 
siRNA refers to the synthetic generation of RNA interference. siRNA can be easily and 
rapidly transfected into cells to reduce the expression of a specific gene at the mRNA level. 
Unfortunately, siRNAs might exert unspecific binding to similar sequences to those of the 
target gene to cause so called off-target effects. Thus, it is better to use at least two different 
siRNAs to target one gene. Another challenge for this technique is innate immunity which 
may influence the knockdown efficiency in different cell types, for example, the knockdown 
efficiency of AP-1 in MDAMB231 cells poorer than BT549 cells.  
3.6 Cell proliferation assays 
In this thesis, we use two methods, BrdU (Bromodeoxyuridine-labeling) and WST-1 (2 - (4-
iodophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2Htetrazolium, mono-sodium salt), to 
measure cell proliferation. BrdU is a common method to measure cell proliferation where the 
thymidine analog reagent, BrdU, incorporates into DNA during the S-phase of the cell cycle. 
BrdU has a high labeling efficiency and can be directly detected under the microscope. WST-
1 is a method to measure cell viability through the amount of a soluble formazan salt that is 
related to the metabolic activity of living cells that can be determined in an ELISA plate 
reader. Data from WST-1 is dependent on the number of living cells and the incubation time 
after the WST-1 solution added into the medium. 
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3.7 Cell invasiveness 
To study cell invasion ability, we choose to use BD BioCoat
TM
 Matrigel Invasion Chambers 
which is a low throughput and highly efficient quantitative method. The results are dependent 
on the cell types because different cell types invade at different rates, and are also dependent 
on specific conditions, such as incubation time, cell seeding density and chemoattractant. In 
this thesis, we found that TNBC cells in the upper chamber with 0% FBS medium migrated to 
the lower chamber containing 10% FBS medium and the number of cells in the lower 
chamber was determined after 24 hours. 
3.8 Apoptosis assay 
In this thesis, we use two methods to detect apoptosis. One is to measure the expression of 
cleaved caspase 3, which is a marker of apoptosis, at the protein level using Western blot 
analysis. Another method is the Cell Death Detection ELISA
PLUS
 kit from Roche that 
measures the amount of nucleosomes from living cells. Compared to Western blot based 
cleaved caspase 3 assay, the Cell Death Detection ELISA
PLUS
 kit is more sensitive. β-actin is 
used as internal control to quantitate the expression of cleaved caspase 3, whereas for the Cell 
Death Detection ELISA
PLUS
 kit, it is important that the number of cells in different samples is 
equal before measuring the apoptosis, as the kit is a colorimetric assay.  
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4 RESULTS AND DISSCUSSION 
4.1 PAPER I: Interplay between AP-1 and estrogen receptor α in regulating gene 
expression and proliferation networks in breast cancer cells 
ERα mediates a proliferative effect in ER-positive breast cancer. Studies of mapping ER-
binding regions show that AP-1 motifs are enriched within the regions bound by ERα in 
breast cancer cells (178, 179). AP-1 has been reported to play a critical role in regulating 
breast cancer cell proliferation (134, 140). However, the interplay between ERα and AP-1 
signaling pathways at the chromatin level is still unclear. Thus, in paper I we addressed the 
role of AP-1 in the gene expression programs including those controlled by estrogen-activated 
ERα. 
We used MCF-7 cells and silenced c-Fos expression through RNA interference system. 
Changes in gene expression were studied using microarray and real-time PCR. Our analysis 
identified 37% of all estrogen-regulated genes were attenuated by silencing of c-Fos. In 
addition, among the genes which were regulated by ERα, 25% of ERα-induced genes and 47% 
of ERα-repressed genes were affected by c-Fos knockdown. These results suggest that c-Fos 
is a major contributor to ERα-mediated gene regulation. 
Gene ontology analysis of all ERα regulated genes that were affected by c-Fos knockdown 
showed that the most overrepresented category for E2-induced genes was related to the G1-S 
transition of the mitotic cell cycle, and for E2-repressed genes related to negative regulation 
of cell proliferation. We evaluated enrichment of specific gene functions for the groups of 
genes whose estrogen regulation was affected by c-Fos knockdown and found proliferation 
highest ranked. These findings implicate a critical role of c-Fos in the regulation of cell 
proliferation and the mitogenic effect of E2 in ERα-positive breast cancer cells. 
In breast cancer cells, it has been reported that ERα promotes cell proliferation by regulating 
the expression of E2F1 that is well known for its involvement in cell proliferation, 
differentiation and apoptosis (180, 181). In this study, pathway analysis revealed that 
silencing of c-Fos downregulated an E2F1-dependent pro-proliferative gene network. 
Additionally, ChIP-qPCR assays showed for the first time that c-Fos and ERα can cooperate 
in regulating E2F1 gene expression by binding to regulatory elements in the E2F1 promoter.  
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To study the molecular details of the cross talk between AP-1 and estrogen signaling, we 
identified PKIB (cAMP-dependent protein kinase inhibitor-β) as a novel ERα/AP-1 target 
molecule. PKIB has been reported to promote cell proliferation in prostate cancer (182). 
WST-1 assay and bromodeoxyuridine (BrdU)-labeling experiments showed that PKIB 
silencing inhibits cell proliferation in ER-positive breast cancer cells. In addition, using the 
Oncomine database we found that the expression of PKIB is higher in ERα-positive compared 
to ERα-negative breast cancer tissues. 
In conclusion, we demonstrated that AP-1 is a major contributor to ERα-mediated gene 
regulation. We identified PKIB as a novel ERα/AP-1 target molecule that is important for 
growth of breast cancer cells. 
4.2 PAPER II: Genome-wide profiling of AP-1-regulated transcription provides 
insights into the invasiveness of triple-negative breast cancer  
AP-1 plays a key role in a variety of cellular processes. In paper I was shown that AP-1 is a 
major contributor to ERα-mediated gene regulation and promotes cell proliferation. It has 
been reported that compared to ER-positive breast cancer, one of the AP-1 family members, 
Fra-1, is overexpressed and involved in cell proliferation, invasion and migration in ER-
negative breast cancer cells (140). However, mechanism of action of AP-1 in TNBC remains 
largely unknown. In this study, we aimed to gain a genome-wide map of AP-1 binding and 
investigate mechanisms underlying AP-1-mediated gene regulation in TNBC cells. 
First, using publicly available gene expression profiling datasets we observed that among all 
of the AP-1 family members, Fra-1 is overexpressed in basal-like breast cancer which is 
described as very similar to TNBC (183), and associated with poor prognosis. Data from 
Western blot and qPCR showed that both c-Jun and Fra-1 were highly expressed in TNBC 
cell lines.  
We choose as our major cell model one of the analyzed TNBC cell lines, BT549 which 
represents basal-like subtype breast cancer based on global gene expression analysis (184). In 
addition, we found that this cell line had a high transfection efficiency of siRNA compared to 
other TNBC cell lines (Hs578T and MDAMB231). Based on this cell model, we identified 
11670 Fra-1 binding regions and 14201 c-Jun binding regions, and that most of them overlap. 
This suggested that they form heterodimers. In addition, the majority of these binding regions 
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were distal to the promoter in intergenic and intronic regions. As expected, de novo DNA 
motif search revealed that the AP-1 motif was the most enriched motif, 58% of Fra-1 binding 
regions and 47% of c-Jun binding regions. 
Global gene expression microarray analysis for TNBC cells upon Fra-1 or c-Jun knockdown 
was used to gain further insight into AP-1-regulated transcriptional networks. Our analysis 
identified differential expression of 419 and 690 genes upon depletion of Fra-1 and c-Jun, 
respectively. Among these genes, 222 genes regulated by both Fra-1 and c-Jun were 
associated with cytokine-mediated signaling, type I interferon-mediated signaling, chemotaxis, 
cell adhesion, immune response, cell junction assembly, adherens junction organization and 
inflammatory response.  
Moreover, we found that the proliferative phenotypes of TNBC cells were inhibited upon 
depletion of both Fra-1 and c-Jun. Cluster analysis of Fra-1 and c-Jun common cell 
proliferation target genes revealed that 20 proliferation-repressing genes were up-regulated 
upon Fra-1 and c-Jun knockdown, whereas 7 proliferation-promoting genes were down-
regulated. Among these genes, the CLCA2 (chloride channel accessory 2) gene was the most 
up-regulated transcript upon Fra-1 and c-Jun knockdown and shown to play an important role 
in inhibition of cancer cell migration and invasion (185, 186). We further found that Fra-1 and 
c-Jun repress CLCA2 expression through direct binding to its intron region to promote cell 
proliferation. 
In addition, silencing of Fra-1 and c-Jun reduced the invasion ability both in vitro and in vivo. 
It is known reported that ZEB2 represses the transcription of E-cadherin that is one of the 
hallmarks of EMT resulting in metastasis and invasion (187, 188). In this study, we showed 
that ZEB2 was one of AP-1 direct target genes and was overexpressed in TNBC cells. 
In an effort to elucidate the mechanism behind AP-1 transcriptional activity in TNBC cells, 
two signaling pathways, PI3K/Akt and MAPK/ERK that are known to be activated and are  
associated with a poor prognosis in TNBC (189, 190), were studied by using two 
pharmacologic inhibitors. Our results showed that high PI3K/Akt or MAPK/ERK activity 
positively regulated Fra-1 and c-Jun expression and was associated with increased AP-1 
transcriptional activity in TNBC cells. 
Taken together, we found that AP-1 is overexpressed in TNBC and associated with poor 
prognosis. AP1 repressed CLCA2 expression through direct binding to its intron region to 
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promote cell proliferation. Furthermore, we confirmed that AP-1 mediates down-regulation of 
E-cadherin through direct transcriptional induction of ZEB2 (Figure 11). 
                             
 
Figure 11. Proposed model of AP-1 promoting cell proliferation and invasion in TNBC.  
4.3 PAPER III: AP-1-mediated chromatin looping regulates ZEB2 transcription: new 
insights into TNFα-induced epithelial-mesenchymal transition in triple-negative 
breast cancer 
TNFα is an inflammatory cytokines is highly expressed in breast tumors as compared with 
normal tissues and involved in EMT in breast cancer (191). To expand our finding in paper II 
we decided to dissect the AP-1 – ZEB2 axis in TNFα-induced EMT in TNBC cells. 
Two different TNBC cell lines, BT549 and Hs578T, were used as cell models in this study. 
First, we found that stimulation of cells with TNFα resulted in morphological changes of 
TNBC cells and the expression of EMT markers, confirming that TNFα induces EMT in our 
model TNBC cells. Furthermore, we confirmed our hypothesis that TNFα-mediated EMT in 
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TNBC cells is dependent on AP-1 – ZEB2 signaling through PI3K/Akt and MAPK/ERK 
pathways. 
Based on published spliced transcripts, two alternatively spliced 5’UTR isoforms of the ZEB2 
gene, referred to as exon 1a (from ENST00000558170) and exon 1b (from 
ENST00000409487), were found to be expressed in breast tumor samples and highly 
expressed in TNBC cell lines which is in agreement with our previous findings that ZEB2 
was overexpressed in TNBC cell lines.  
Based on our AP-1 ChIP-seq data, ZEB2 gene harbors only one AP-1 binding site that is 
located in the promoter 1b region. However, both of these two transcripts were regulated by 
AP-1 with or without TNFα treatment, which indicates that AP-1 binding to promoter 1b also 
regulates the activity of promoter 1a by long range chromosomal interactions. We performed 
the chromosome conformation capture (3C) assay to confirm our hypothesis. Our results 
showed that AP-1, when activated by TNFα, binds to a site in promoter 1b of the ZEB2 gene 
where it regulates the expression of both promoter 1b and 1a, the latter via mediating long 
range chromatin interactions (Figure 12). 
                                 
Figure 12. Proposed model of AP-1-mediated chromatin looping regulating ZEB2 transcription. 
In summary, our study not only reveals a critical mechanism underlying inflammation-
induced metastatic potential in TNBC but also suggests AP-1, its upstream regulatory 
signaling pathways ERK and Akt and ZEB2 as potential drug targets for reversing EMT, the 
key event in the acquisition of invasive potential. 
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4.4 PAPER IV: AP-1 is a key regulator of TNFα-mediated triple-negative breast 
cancer progression 
TNFα as a pro-inflammatory cytokine can facilitate tumor progression and metastasis. 
However, the molecular mechanisms of TNFα-mediated TNBC progression are not well 
described. From our previous studies, we found that AP-1 proteins, mainly Fra1 and c-Jun, 
are overexpressed in TNBC compared to the other subtypes of breast cancer. Also, TNFα 
triggered EMT through up-regulation of ZEB2 via AP-1 activation in TNBC. Although it has 
long been known that AP-1 plays a key role in response to inflammatory signaling, the 
molecular mechanisms are still unclear. In paper IV was explored the AP-1 cistrome and 
transcriptome in response to TNFα, this to better understand the mechanism underlying 
inflammation-induced tumor progression. 
In this study, we used BT549 cells as our cell model, and Hs578T as another TNBC cell line 
to confirm our results. To begin to explore the AP-1 cistrome and transcriptome in response to 
TNFα, we performed ChIP-seq to map the c-Jun binding regions in BT549 cells upon TNFα 
treatment for 3 hours. First, we identified 13800 and 4570 c-Jun binding regions in TNFα 
stimulated and non-stimulated cells, respectively. As expected, de novo DNA motif search 
revealed that AP-1 motif was the most enriched motif in c-Jun cistromes in both TNFα treated 
and non-treated groups. The major genomic positions of c-Jun binding regions were found in 
intergenic and intronic parts of genes. Through use of the genomics regions enrichment of 
annotation tool (GREAT), we found that c-Jun binding regulates apoptosis signaling 
pathways and oxidative stress responses upon TNFα stimulation. 
To identify global gene expression regulated by c-Jun upon TNFα stimulation, we used 
microarray and real-time PCR. BT549 cells were transfected by siRNA to knockdown the 
expression of c-Jun with or without TNFα treatment. We identified that the expression of 
1192 genes and 940 genes in control cells and c-Jun-depleted cells, respectively, were 
differentially regulated by TNFα treatment. By comparing the si_control to si_c-Jun group in 
the presence of TNFα, we identified 616 genes that were affected by decreased c-Jun 
expression. Overlapping these 616 genes with TNFα-induced c-Jun binding regions within 
20kb upstream or downstream of a known transcriptional start site (TSS), we identified 204 
direct c-Jun target genes in TNFα-stimulated cells, such as EGR2, ZEB2, MMP9 and 
TNFAIP8 which were also confirmed by qPCR. Gene ontology analysis of these 204 genes 
showed that significantly overrepresented categories were related to cell proliferation, 
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phosphorylation, cell adhesion, cell motion, intracellular signaling cascade, gene expression, 
apoptosis and cellular homeostasis, but not related to the inflammatory response. 
To further study the functions of c-Jun in response to TNFα, knockdown of c-Jun was done 
and cells were treated with or without TNFα. We found that c-Jun knockdown sensitized 
TNBC cells to TNFα-induced apoptosis, and inhibits TNFα-induced cell invasion. Next, we 
wanted to identify c-Jun direct target genes with known functions in apoptosis and cell 
invasion. Twenty-three anti-apoptotic genes such as Ninj1, 13 pro-apoptotic genes such as 
CDK5, 14 pro-invasion genes such as ZEB2 and 5 anti-invasion genes such as CLCA2 were 
identified. Furthermore, high expressions of these pro-invasion genes were associated with 
poor outcome in breast cancer, especially in basal tumors. To further describe the mechanisms 
of TNFα-regulated cancer progression via c-Jun activation, we focused on the c-Jun direct 
target gene Ninj1. It has been shown that Ninj1 deficiency suppresses cell proliferation but 
enhances apoptosis and premature senescence in a p53-dependent manner in colon cancer 
cells (192). In line with this, we found that Ninj1 knockdown enhanced apoptosis and reduced 
the invasiveness of TNBC cells upon TNFα stimulation. Furthermore, the effect of c-Jun 
knockdown on apoptosis and cell invasion was reversed by overexpression of Ninj1. Together, 
these results demonstrate that the Ninj1 gene, which is transcriptionally regulated by c-Jun, 
drives TNFα-induced malignant characteristics of TNBC cells. 
TNFα is well known as a central regulator of inflammation. In our study, we identified a 
region of TNFα-induced c-Jun binding sites flanking the CXC chemokine cluster (IL8, 
CXCL1, CXCL2 and CXCL3) on chromosome 4. However, we found that c-Jun is not 
essential for expression of these chemokine genes. It is well known that NFκB is a master 
effector of TNFα-induced inflammation (193, 194). The above described CXC chemokine 
cluster region was earlier found to harbor NFκB binding sites induced by IL1 (195). Based on 
de novo DNA motif analysis, we found that the NFκB motif was enriched in the presence of 
TNFα. In addition, TNFα induced recruitment of NFκB to the CXC chemokine gene cluster, 
and knockdown of NFκB dramatically reduced the expression of these chemokine genes upon 
TNFα stimulation. Accordingly, gene ontology analysis did not find c-Jun direct target genes 
associated with inflammatory response in the presence of TNFα, suggesting that NFκB 
activation was essential for induction of the chemokine gene expression in response to TNFα. 
ChIP-qPCR was used to further investigate the relationship between NFκB and c-Jun 
recruitment to the CXC chemokine cluster. Knockdown of NFκB reduced the recruitment of 
c-Jun to the promoters of chemokine genes. In contrast, knockdown of c-Jun increased the 
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recruitment of NFκB. These findings indicate that NFκB might be a pioneer factor for c-Jun 
recruitment to this gene cluster (Figure 13).  
                                 
Figure 13. NFκB as a pioneer factor for AP-1 recruitment to the chemokine gene cluster. The function of 
NFκB is to induce and maintain an open chromatin architecture, then AP-1 and other transcription factors can 
bind to DNA to regulate gene expression. 
In conclusion, we describe for the first time the inflammatory cistrome for the AP-1 
transcription factor c-Jun in TNBC cells. Furthermore, we demonstrate that AP-1 activation in 
TNBC cells contributes to inflammation-induced tumor progression, rather than the 
inflammatory response. We identify a set of c-Jun-regulated pro-invasion genes that are 
strongly associated with clinical outcomes in TNBCs. We characterize the Ninj1 gene, which 
is transcriptionally regulated by c-Jun to drive TNFα-mediated malignant characteristics of 
TNBC cells. 
35 
 
5 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
5.1 AP-1 in ER-positive breast cancer 
AP-1 plays important roles in carcinogenesis and cancer progression. It is clear that AP-1 is 
involved in ER signaling pathways to modulate gene expression in ERα-positive breast cancer. 
In this thesis, we found that one of the AP-1 family members, c-Fos, is a major contributor to 
ERα-mediated gene regulation. Moreover, we identified a novel ERα/AP-1 target molecule, 
PKIB, which is important in breast cancer growth. In addition, evidence is provided that c-Fos 
is involved in E2-induced activation of E2F1 expression through binding to the E2F1 
promoter to regulate cell cycle progression.  
Thus, a detailed understanding of ERα/AP-1/E2F1 network in relation to proliferation of 
breast cancer cells will facilitate identification of components of this network suitable as drug 
targets in order to inhibit breast cancer cell proliferation. In addition, it has earlier been 
reported that up-regulation of AP-1 is associated with tamoxifen resistance in MCF7 breast 
cancer cells and ERα-positive breast tumors (135-137). A more clear understanding of the 
mechanism of AP-1 signaling may suggest novel strategies to overcome tamoxifen resistance. 
5.2 AP-1 in TNBC 
Compared to other subtypes of breast cancer, TNBC has yet no specific target and is only 
sensitive to chemotherapy and radiation therapy. Patients with TNBC experience often relapse 
more quickly and have worse prognosis compared to other breast cancer subtypes (123).  
The most important finding in this thesis is that AP-1 is overexpressed in TNBC and 
associated with poor prognosis. Also that AP-1 represses CLCA2 expression through direct 
binding to its intron region to promote cell proliferation and that AP-1 mediates 
downregulation of the important EMT regulator, E-cadherin, through direct transcriptional 
induction of its repressor ZEB2. 
TNFα, one of the inflammatory cytokines, promotes tumor development and progression 
(191). In this thesis, is found that TNFα induces EMT in TNBC cells via activation of AP-1 
signaling and expression of the EMT regulator ZEB2. Furthermore, we defined for the first 
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time the inflammatory cistrome of the AP-1 transcription factor c-Jun and demonstrated that 
AP-1 activation in TNBC cells contributes to inflammation-induced tumor progression, rather 
than inflammatory response. A set of c-Jun-regulated pro-invasion genes was identified that 
are strongly associated with clinical outcomes in TNBCs. Described is also TNFα-induced c-
Jun activation of Ninj1 gene expression driving TNBC cell tumor progression.  
Together, these results suggest that AP-1 is an important and a valid therapeutic target for 
breast cancer. There are several AP-1 inhibitors that are currently under intense development 
pre-clinically and clinically in many therapeutic areas. One of the inhibitors of AP-1, T-5224, 
has advanced into human phase II clinical trials for rheumatoid arthritis (196). Future studies 
should focus on to identify if AP-1 inhibitors could be used in treatment of breast cancer.   
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